Trial · NCT05267886
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
NCT05267886, Phase 4, Recruiting, Ottawa Heart Institute Research Corporation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock. Trials, record NCT05267886. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05267886
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
- NCT number
- NCT05267886
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 346 participants, estimated
- Lead sponsor
- Ottawa Heart Institute Research Corporation
- Conditions
- Shock, Cardiogenic
- Interventions
- Dobutamine, Milrinone, Normal Saline
- First posted
- 2022-03-04
- Last updated
- 2026-05-01
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Primary composite outcome | Through duration of hospitalization, up to 12 weeks following admission | The primary outcome will be a composite of: 1. All-cause mortality during the hospitalization 2. Measured within the first 12 hours of starting the study intervention, any of: 1. Sustained hypotension (mean arterial pressure ≤55mmHg) or sustained requirement of high dose vasopressors (norepinephrine \>0.2 mcg/kg/min or norepinephrine 0.2 mcg/kg/min plus any additional agent) with any escalation in dose from time of randomization, for \>/= 60 minutes 2. Lactate greater than 3.5 mmol/L at 6 hours or thereafter 3. Need for mechanical circulatory support device 4. Atrial or ventricular arrhythmia leading to emergent electrical cardioversion 5. Resuscitated cardiac arrest |
| Secondary | All-cause in-hospital mortality | Through duration of hospitalization, up to 12 weeks following admission | Death resulting from any cause during hospitalization |
| Secondary | Renal failure requiring new initiation of renal replacement therapy | Through duration of hospitalization, up to 12 weeks following admission | Requiring new initiation of renal replacement therapy |
| Secondary | Need for cardiac transplant or mechanical circulatory support | Through duration of hospitalization, up to 12 weeks following admission | Identification of needing a cardiac transplant or mechanical circulatory support |
| Secondary | Atrial or ventricular arrhythmia leading to emergent electrical cardioversion | Through duration of hospitalization, up to 12 weeks following admission | Requiring emergent electrical cardioversion for atrial or ventricular arrhythmia |
| Secondary | Resuscitated cardiac arrest | Through duration of hospitalization, up to 12 weeks following admission | Cardiopulmonary arrest requiring chest compressions and/or defibrillation with successful return of spontaneous circulation (ROSC) |
| Secondary | Non-fatal myocardial infarction | Through duration of hospitalization, up to 12 weeks following admission | Non-fatal myocardial infarction |
| Secondary | Stroke or transient ischemic attack | Through duration of hospitalization, up to 12 weeks following admission | Defined as an episode of focal or global neurological deficit as diagnosed by a neurologist |
| Other | Need for non-invasive or invasive mechanical ventilation | Through duration of hospitalization, up to 12 weeks following admission | Need for non-invasive or invasive mechanical ventilation after randomization |
| Other | Arrhythmia requiring pharmacologic intervention | Through duration of hospitalization, up to 12 weeks following admission | Atrial or ventricular arrhythmias requiring initiation of pharmacologic intervention (intravenous or oral anti-arrhythmic therapy) |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05267886
GET https://conductscience.org/api/trials/v1/NCT05267886/registered